NCT05128734 2025-12-15
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
AHS Cancer Control Alberta
Phase 2 Not yet recruiting
Clinical Trials
4 trialsNCT07187674 2025-09-23
The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
Harbin Medical University
Phase NA Not yet recruiting
NCT07113964 2025-08-11
QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT07005583 2025-06-05
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting